Monetary Management Group Inc. Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Monetary Management Group Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 19.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,250 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the period. Monetary Management Group Inc.’s holdings in Pfizer were worth $988,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. PSI Advisors LLC lifted its position in shares of Pfizer by 1.4% in the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its stake in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the period. Lipe & Dalton boosted its holdings in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 401 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PFE shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday. UBS Group decreased their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Stock Down 4.1 %

NYSE PFE opened at $21.57 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business has a 50 day moving average price of $25.33 and a two-hundred day moving average price of $26.45. The stock has a market cap of $122.32 billion, a PE ratio of 15.30, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.